Implications Of Cellular Senescence In Parkinson’S Disease: Recent Developments And Future Directions
As we age, our bodies undergo various changes, and one such change at the cellular level is called cellular senescence. Imagine a cell that has decided to retire; it stops dividing, but it doesn’t just sit there quietly. Instead, it becomes quite active, releasing a mix of molecules that can cause inflammation and damage to surrounding healthy cells. This collection of secreted factors is known as the senescence-associated secretory phenotype, or SASP.
Parkinson’s disease is a progressive brain disorder that primarily affects movement, resulting from the loss of specific brain cells that produce dopamine, a crucial chemical messenger. While the exact causes are complex, aging is the most significant risk factor. Recent research highlights a compelling connection between these “retired” senescent cells and the development and progression of Parkinson’s. These senescent cells accumulate in the aging brain, particularly in areas affected by Parkinson’s. Their harmful secretions contribute to a chronic inflammatory environment and other damaging processes that ultimately lead to the death of vulnerable dopamine-producing neurons.
Understanding this link opens up exciting new avenues for treatment. Instead of just managing symptoms, scientists are exploring therapies that specifically target these senescent cells. These approaches include “senolytics,” which are drugs designed to selectively eliminate senescent cells, and “senomorphics,” which aim to modify the harmful substances they release. Some of these therapies are already being tested in clinical trials for other age-related conditions, offering hope for future disease-modifying treatments for Parkinson’s disease.
Source: link to paper